ArticleInternal medicine (Tokyo, Japan)2025
Treatment of Anti-myelin-associated Glycoprotein Neuropathy with Tirabrutinib and a 3-year Follow-up.
Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-MAG-associated neuropathy: a case report and literature review.BMC neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 69-year-old man was admitted to our hospital because of progressive numbness in the lower legs and fingertips as well as a burning sensation in the soles of both feet. The patient was diagnosed with anti-myelin-associated glycoprotein (anti-MAG) neuropathy based on increased serum IgM levels and anti-MAG antibody titers. Atypical pulmonary mycobacteriosis was also suspected. Following treatment with tirabrutinib (a second-generation Bruton tyrosine kinase inhibitor), his symptoms improved and the anti-MAG antibody titer and IgM levels decreased. Tirabrutinib may therefore be an effective treatment option for anti-MAG neuropathy, particularly in patients at risk of infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.